NEOADJUVANT CHEMOTHERAPY AND OPERATION FOR INVASIVE MASAOKE STAGE Ⅲ AND Ⅳa THYMOMA

作     者：谭黎杰 仇德惠 王群 徐正浪 徐松涛 TAN Lijie;QIU Dehui;WANG Qun;XU Zheng-lang;XU Song-tao

作者机构：Department of Thoracic Surgery Zhong Shan Hospital Fudan University Medical College Shanghai 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2001年第13卷第2期

页      面：132-135页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Thymoma Neoadjuvant chemotherapy Operation 

摘      要：Objective: Evaluation the role of neoadjuvant chemotherapy in invasive thymoma. Methods: 14 patients with invasive thymoma(Masaoka stage Ⅲ in 12 and Ⅳa in 2) were treated with neoadjuvant chemotherapy by CAVP for 3-4 cycles (cyclophosphamide 600mg/m2 D1, adramycin 30mg/m2 or epi-adramycin 40mg/m2 D1, vincristine 0.6mg/m2 D1 or vindestine 3mg/m2 D1、D8, cisplatin 30mg/m2 D1、2、3)。After chemotherapy, all patients underwent operation in 1-3 months. We performed 10 sternotomies and 4 anterolateral thoracotomies. Radiotherapy was administrated with total dose 50-60Gy in all patients except for those who were pathologically complete remission. The group was followed up by 6 months to 3 years. Results :After chemotherapy, 5 patients(35.7%) had a complete remission(CR) and 9 patients(64.3%) had a partial remission(PR)。At operation, 9 patients had radical resection and 5 had partial resection. Postoperative pathological examination found only fibrosis in 5 patients with CR by chemotherapy. All patients were still alive except 2 patients died from visceral metastasis after 18 months and 2 years respectively. Conclusion: Neoadjuvant chemotherapy can increase the resectability of stage Ⅲ and Ⅳa invasive thymoma. A longer follow-up and a larger number of patients are needed to determine the impact of this treatment on long-term survival.